Evidence map›Paper›PMID 35587922›Full record

ArticlePloS one2022

Tetanus seroprotection among children in the Democratic Republic of the Congo, 2013-2014.

Alvan Cheng, Angie Ghanem-Uzqueda, Nicole A Hoff, Hayley Ashbaugh, Reena H Doshi, Patrick Mukadi, Roger Budd, Stephen G Higgins, Christina Randall, Sue Gerber and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Alvan ChengDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California, United States of America.ORCID 0000-0003-2281-1798
Angie Ghanem-UzquedaDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California, United States of America.
Nicole A HoffDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California, United States of America.ORCID 0000-0002-1770-6304
Hayley AshbaughDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California, United States of America.ORCID 0000-0002-8530-0904
Reena H DoshiDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California, United States of America.
Patrick MukadiSchool of Medicine, Kinshasa University, Kinshasa, Democratic Republic of the Congo.ORCID 0000-0001-9312-9345
Roger BuddDYNEX Technologies Incorporated, Chantilly, Virginia, United States of America.
Stephen G HigginsLentigen Technology, Incorporated, Gaithersburg, Maryland, United States of America.
Christina RandallDYNEX Technologies Incorporated, Chantilly, Virginia, United States of America.
Sue GerberBill and Melinda Gates Foundation, Seattle, Washington, United States of America.
Michel KabambaExpanded Program on Immunization, Ministry of Public Health, Kinshasa, Democratic Republic of the Congo.
Guilluame Ngoie MwambaVillageReach, Kinshasa, Democratic Republic of the Congo.
Emile Okitolonda-WemakoyKinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo.
Jean Jacques Muyembe-TanfumNational Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo.
Anne W RimoinDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California, United States of America.
University of California, Los Angeles · USMinistry of Public Health · CDGates Foundation · USLentigen Technology (United States) · USNational Institute of Biomedical Research · CDUniversity of Kinshasa · CD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTetanus is a potentially fatal disease that is preventable through vaccination. While the Democratic Republic of the Congo (DRC) has continued to improve implementing routine vaccination activities throughout the country, they have struggled to maintain high childhood vaccine coverage. This study aims to examine the seroprevalence of tetanus in children 6 to 59 months to identify areas for intervention and improvement of vaccination coverage.

methodsIn collaboration with the 2013-2014 Demographic and Health Survey, we assessed the seroprevalence of tetanus antibodies among children in the DRC. Dried blood spot samples collected from children 6-59 months of age were processed using a prototype DYNEX Multiplier® chemiluminescent automated immunoassay instrument with a multiplex measles, mumps, rubella, varicella and tetanus assay. Multivariable logistic regression was used to determine factors associated with tetanus vaccination and seroprotection.

resultsOverall, 36.1% of children 6-59 months of age reported receiving at least 1 dose of tetanus vaccine while 28.7% reported receiving 3 doses; tetanus seroprotection was 40%. Increasing age in children was associated with decreased tetanus seroprotection, but increased number tetanus vaccinations received. Factors related to increased tetanus seroprotection included number of children in the household, wealth index of the family, urban residence compared to rural, level of maternal education, and province and geography.

conclusionsOur findings in this nationally representative sample indicate that serology biomarkers may help identify children who are not fully immunized to tetanus more accurately than reported vaccination. While children may be captured for routine immunization activities, as children age, decreasing seroprevalence may indicate additional need to bolster routine vaccination activities and documentation of vaccination in school aged children. Additionally, the study highlights gaps in rural residential areas and vaccination coverage based on maternal education, indicating that policies targeting maternal education and awareness could improve the coverage and seroprevalence of tetanus antibodies in the DRC.

Indexed as

MeaslesTetanusChildDemocratic Republic of the CongoHumansInfantSeroepidemiologic StudiesTetanus ToxoidVaccinationTetanus Toxoid

Identifiers

PMID35587922
PMCPMC9119496
OpenAlexW4280601920

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.